Effects of Astragalus polysaccharide on imiquimod-induced psoriasiform dermatitis in mice and its mechanisms

doi:10.12047/j.cjap.6214.2022.022

Abstract

Abstract: Objective: To investigate the effects and mechanisms of Astragalus polysaccharide on improving imiquimod-induced psoriasiform dermatitis in mice. Methods: Forty healthy female C57BL/6 mice were randomly divided into 5 groups, including blank control group, model group, astragalus polysaccharide high-dose group (200 mg/kg), medium-dose group (100 mg/kg) and low-dose group (50 mg/kg), with 8 mice in each group. The mice in model group and astragalus polysaccharide treatment group were treated with 5% imiquimod cream on the back to induce psoriasiform dermatitis. PASI score was monitored, and the secretion of inflammatory factors was determined by ELISA. The secretion of inflammatory factors was closely related to the infiltration of macrophages. The infiltration of macrophages in skin was detected by flow cytometry to further explore the effect of different concentrations of APS on psoriasis. Results: Compared with control group, the PASI score and the serum levels of TNF-α, IL-1β and IL-6 were increased significantly (P＜0.05), and the infiltration of macrophages in skin tissue was increased significantly in model group (P＜0.05). Compared with model group, the PASI score was decreased significantly (P＜0.05), and the serum levels of TNF-α, IL-1β and IL-6 were down-regulated significantly in astragalus polysaccharide high-dose and medium-dose groups (P＜0.05). The infiltrating macrophages in skin tissue were decreased significantly in Astragalus polysaccharide high-dose group (P＜0.05). Conclusion: Astragalus polysaccharide improve psoriasiform dermatitis in mice by inhibiting the infiltration of macrophages in skin tissue and decreasing the secretion of TNF-α, IL-1β and IL-6 in serum.

Key words: astragalus polysaccharide, imiquimod, psoriasiform dermatitis, macrophage infiltration, mice

CLC Number:

CHEN Ruo-xi, ZHENG Sheng, GUO Chun-yan, ZHANG Qiang. Effects of Astragalus polysaccharide on imiquimod-induced psoriasiform dermatitis in mice and its mechanisms[J]. CJAP, 2022, 38(2): 154-159.

References

[1] Li Q, Liu W, Gao S, et al. Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist [J]. BMC Immunol, 2021, 22(1): 11.
[2] He X, Zhu B, Xie W, et al. Amelioration of imiquimod-induced psoriasis-like dermatitis in mice by DSW therapy inspired hydrogel [J]. Bioact Mater, 2021, 6(2): 299-311.
[3] Kiss B, Szanto M, Hegedus C, et al. Poly(ADP-ribose) polymerase-1 depletion enhances the severity of inflammation in an imiquimod-induced model of psoriasis [J]. Exp Dermatol, 2020, 29(1): 79-85.
[4] Guo J, Liu Y, Guo X, et al. Depressive-like behaviors in mice with Imiquimod-induced psoriasis [J]. Int Immunopharmacol, 2020, 89(Pt B): 107057.
[5] Choi CW, Kim BR, Yang S, et al. Regulatory T cells suppress skin inflammation in the imiquimod-induced psoriasis-like mouse model [J]. J Dermatol Sci, 2020, 98(3): 199-202.
[6] Singh TP, Zhang HH, Hwang ST, et al. IL-23- and imiquimod-induced models of experimental psoriasis in mice[J]. Curr Protoc Immunol, 2019, 125(1): e71.
[7] Sun J, Wei S, Zhang Y, et al. Protective effects of astragalus polysaccharide on sepsis-induced acute kidney injury[J]. Anal Cell Pathol(Amst), 2021, 2021: 7178253.
[8] Li C, Pan XY, Ma M, et al. Astragalus polysacharin inhibits hepatocellular carcinoma-like phenotypes in a murine HCC model through repression of M2 polarization of tumour-associated macrophages[J]. Pharm Biol, 2021, 59(1): 1533-1539.
[9] Zhang G, Fang H, Li Y, et al. Neuroprotective effect of astragalus polysacharin on streptozotocin(STZ)-induced diabetic rats[J]. Med Sci Monit, 2019, 25: 135-141.
[10] Shao F, Tan T, Tan Y, et al. Andrographolide alleviates imiquimod-induced psoriasis in mice via inducing autophagic proteolysis of MyD88[J]. Biochem Pharmacol, 2016, 115: 94-103.
[11] Goenaga-Vazquez Y, Lauck KC, Hebert A. A Therapeutic challenges in managing pediatric psoriasis[J]. Int J Womens Dermatol, 2021, 7(3): 314-318.
[12] Jadali Z. Unfulfilled inflammatory resolution: A key factor in the pathogenesis of psoriasis[J]. Iran J Allergy Asthma Immunol, 2020, 19(4): 337-347.
[13] Zeng J, Chen X, Lei K, et al. Mannan-binding lectin promotes keratinocyte to produce CXCL1 and enhances neutrophil infiltration at the early stages of psoriasis[J]. Exp Dermatol, 2019, 28(9): 1017-1024.
[14] Schuster C, Huard A, Sirait-Fischer E, et al. S1PR4-dependent CCL2 production promotes macrophage recruitment in a murine psoriasis model [J]. Eur J Immunol, 2020, 50(6): 839-845.
[15] Hou Y, Zhu L, Tian H, et al. IL-23-induced macrophage polarization and its pathological roles in mice with imiquimod-induced psoriasis [J]. Protein Cell, 2018, 9(12): 1027-1038.
[16] Li L, Zhang HY, Zhong XQ, et al. PSORI-CM02 formula alleviates imiquimod-induced psoriasis via affecting macrophage infiltration and polarization [J]. Life Sci, 2020, 243: 117231.
[17] Papp KA, Gooderham M, Jenkins R, et al. Granulocyte-macrophage colony-stimulating factor(GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody [J]. Br J Dermatol, 2019, 180(6): 1352-1360.
[18] Leite Dantas R, Masemann D, Schied T, et al. Macrophage-mediated psoriasis can be suppressed by regulatory T lymphocytes [J]. J Pathol, 2016, 240(3): 366-377.
[19] Ropke M, Bulai Livideanu C, Kaldate R, et al. Changes in interleukin-17A, macrophage-derived chemokine and adiponectin following treatment of psoriasis with calcipotriol plus betamethasone dipropionate aerosol foam: results from the PSO-ABLE study [J]. Br J Dermatol, 2018, 178(1): e33-e34.
[20] Deng G, Chen W, Wang P, et al. Inhibition of NLRP3 inflammasome-mediated pyroptosis in macrophage by cycloastragenol contributes to amelioration of imiquimod-induced psoriasis-like skin inflammation in mice [J]. Int Immunopharmacol, 2019, 74: 105682.
[21] Liu T, Zhang M, Niu H, et al. Astragalus polysaccharide from astragalus melittin ameliorates inflammation via suppressing the activation of TLR-4/NF-kappaB p65 signal pathway and protects mice from CVB3-induced virus myocarditis [J]. Int J Biol Macromol, 2019, 126: 179-186.
[22] Yue D, You Y, Zhang X, et al. CD30L/CD30 protects against psoriasiform skin inflammation by suppressing Th17-related cytokine production by Vgamma4(+) gammadelta T cells [J]. J Autoimmun, 2019, 101: 70-85.